- Home
- SLN
as 04-18-2025 1:43pm EST
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
| Founded: | 1994 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 123.3M | IPO Year: | N/A |
| Target Price: | $40.80 | AVG Volume (30 days): | 292.1K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.97 - $24.38 | Next Earning Date: | 05-15-2025 |
| Revenue: | $43,258,000 | Revenue Growth: | 36.71% |
| Revenue Growth (this year): | -25.23% | Revenue Growth (next year): | N/A |
Latest Silence Therapeutics Plc American Depository Share News
SLN Breaking Stock News: Dive into SLN Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
3 Promising Penny Stocks With Market Caps Under $200M
Simply Wall St.
17 days ago
Silence Therapeutics plc (NASDAQ:SLN): When Will It Breakeven?
Simply Wall St.
a month ago
Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)
Business Wire
a month ago
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
Zacks
2 months ago
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
Simply Wall St.
2 months ago
Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Business Wire
2 months ago
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Business Wire
2 months ago
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
Compare SLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLN Silence Therapeutics Plc American Depository Share - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.